Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator

[{"selector":"#anim-25be23dc-6353-4155-928a-b5b66c288f87","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f9432c69-b23a-48c2-a352-1bb6609f7af2","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Visus Therapeutics has presented topline data from its Phase 3 BRIO-I trial of BRIMOCHOL™ PF, a treatment for presbyopia.

[{"selector":"#anim-f21700e3-f786-4d54-a25d-77eeb8701345","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. The trial met its FDA primary endpoint for binocular near visual acuity across multiple time points and showed no significant adverse events.

[{"selector":"#anim-db960723-610a-46e3-90f4-c8b1e085048d","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. BRIMOCHOL™ PF demonstrated a statistically significant reduction in pupil size at all time points up to 10 hours.

[{"selector":"#anim-2e59803e-7212-4719-8096-bd1b8f985907","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. The treatment also showed a significant improvement in distance vision at 8 hours, compared to active controls.

[{"selector":"#anim-2cc54a96-4b92-413b-8e07-cdbc6fe63705","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. Study participants reported greater effectiveness of BRIMOCHOL™ PF over its active controls.

[{"selector":"#anim-27e1e685-2676-4605-8a59-42d77b2ea088","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. The trial evaluated the safety and efficacy of the preservative-free ophthalmic solution for presbyopia treatment.

[{"selector":"#anim-b689c4c3-c79f-4caa-9c30-afe5416cef3c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. Visus Therapeutics CEO Ben Bergo sees a clear pathway forward with positive Phase 3 data.

[{"selector":"#anim-793241f4-86eb-48d8-89a4-5a8009ce2836","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. BRIMOCHOL™ PF is the first fixed-dose combination product to achieve statistically significant "contribution-of-elements" in presbyopia.

[{"selector":"#anim-d4d28273-29d7-42ef-8467-a94aeb40c020","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. The treatment was well-tolerated, with less than 10% experiencing headaches and no serious adverse events reported.

[{"selector":"#anim-0cc0e30b-1778-4356-a40f-8d85462c8f96","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. Topline results from the ongoing Phase 3 BRIO-II study are expected in the second half of 2023.

[{"selector":"#anim-c5744347-b24e-4e4e-82d9-54b16a6d6ec4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-0971823e-8a43-41e6-99d5-784915610776","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more